Advertisement
News
Advertisement

Momenta, Baxter form potential $450M generic drug deal(2)

Fri, 12/23/2011 - 2:48pm

Momenta Pharmaceuticals Inc., a Cambridge-based developer of novel and generic drugs, has formed a $33 million collaboration deal with Baxter International Inc. that could balloon to more than $450 million with possible milestone payments included. The agreement centers around the development and commercialization of biosimilars, a form of generic drugs, in the areas of cancer, autoimmune disorders and chronic diseases.

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading